Table 7.
Institute | Number of patients | Important results/conclusions |
---|---|---|
Helsinki University Hospital, Helsinki, Finland. Koljonen et al. [10] | 15 patients | (i) False-negative lymph nodes were found in 30% of the patients. Immunohistochemical reevaluation decreased this figure to 22%. Therefore for MCC, false-negative sentinel lymph nodes can and should be limited by using immunohistochemistry. |
| ||
Memorial Sloan-Kettering Cancer Center, New York, United States. Fields et al. [11] | 153 patients | (i) Factors associated with SLNB positivity are primary tumor size (25% ≤2 cm versus 45% >2 cm; P = 0.02) and presence of LVI (55% versus 4%; P < 0.01). The 2-year CIs of recurrence or death from MCC for LVI-positive patients were 30% and 15%, respectively. No LVI-negative patient experienced recurrence of disease or died of MCC. |
| ||
Westmead Hospital, New South Wales, Australia. Howle and Veness [12] | 16 patients, stage I or II |
(i) 8/16 (50%) had a positive SLN. (ii) 8/16 had a negative SLN and did not undergo any nodal treatment following SLNB. Two of these patients developed nodal relapse, giving a false negative rate of 20%. |
CIs: confidence intervals; LVI: lymphovascular invasion; MCC: Merkel cell carcinoma; SLNB: sentinel node biopsy.